Compositions for treating macular degeneration comprising novel peptides

By developing new peptides with specific amino acid sequences, the problems of poor efficacy and high treatment cost of macular degeneration have been solved, effective inhibition of choroidal neovascularization has been achieved, and the therapeutic effect of macular degeneration has been significantly improved.

CN118984715APending Publication Date: 2024-11-19EYEBIOKOREA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280082653.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-09-21
Filing Date
2022-11-29
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing macular degeneration treatment methods have problems such as poor treatment effect, repeated administration and high cost. Especially for exudative macular degeneration, there is no complete treatment method.

Method used

A novel peptide containing specific amino acid sequences has been developed to inhibit choroidal neoangiogenesis with excellent stability and solubility for the prevention or treatment of macular degeneration. The peptide chain formed by the peptide through specific amino acid combinations, including such as proline, glycine, glutamine, etc., can effectively inhibit the production of choroidal neovascularization.

Benefits of technology

This new peptide significantly inhibits choroidal neovascularization, has excellent stability and solubility, and can effectively prevent or treat macular degeneration, especially in wet macular degeneration, which reduces the size and leakage of the lesion and improves the Retinal function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004891028560000081
    Figure BDA0004891028560000081
  • Figure BDA0004891028560000091
    Figure BDA0004891028560000091
  • Figure BDA0004891028560000141
    Figure BDA0004891028560000141
Patent Text Reader

Abstract

The present invention relates to a composition for preventing or treating macular degeneration comprising a novel peptide. Specifically, the peptide of the present invention has an excellent effect of inhibiting choroidal neovascularization, which is the main cause of macular degeneration, and exhibits excellent stability and solubility, and thus can be developed as an excellent therapeutic agent for macular degeneration.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a composition for preventing or treating macular degeneration comprising a novel peptide. Specifically, the peptide of the present invention has the ability to inhibit choroidal neovascularization, which is the main cause of macular degeneration, and has excellent stability and solubility. Background Art

[0002] The macula is the most important part of the inner nerve layer of the eyeball called the retina. It is the central area of ​​the retina with a radius of about 1.5 mm, where photoreceptors that can sense light are densely packed. Therefore, the macula, as the center of the retina, is responsible for most of the vision. Macular degeneration is a disease in which the macula degenerates due to aging, genetic factors, toxicity, inflammation, etc. With macular degeneration, vision deteriorates, and in severe cases, vision may be completely lost.

[0003] Macular degeneration is mainly divided into non-exudative (dry) and exudative (wet). Non-exudative macular degeneration accounts for 80-90% of all macular degenerations. In most cases, it does not significantly affect vision, except for the manifestation of retinal and choroidal atrophy in the later stage. However, it is necessary to pay attention because it may develop into exudative macular degeneration. Exudative macular degeneration accounts for about 10-20% of all macular degenerations, but if left untreated, vision will deteriorate rapidly, causing many patients to become blind within 2 years of diagnosis.

[0004] Exudative macular degeneration is a stage of choroidal neovascularization, and it is the disease with the highest blindness rate among people over 65 years old because of its extremely poor visual prognosis. The blood vessel layer called the choroid plays a role in supplying nutrients to the retinal layer and removing metabolic substances produced from retinal cells. However, due to aging and other reasons, the blood vessels of the choroid pass through the retinal cells and form abnormally. In this case, the abnormal blood vessels are called choroidal neovascularization. Since these blood vessels are abnormal blood vessels, they are very fragile and easily ruptured, causing exudates and blood to flow out and damage the macular area.

[0005] For the treatment of macular degeneration, in the case of non-exudative macular degeneration, antioxidant vitamins known to slow the progression of macular degeneration are taken, as well as treatment for hypertension, hyperlipidemia, etc., which are risk factors for macular degeneration. In the case of exudative macular degeneration, thermal laser photocoagulation, photodynamic therapy, antibody injection, vitrectomy, etc. are included, but there is no complete treatment method at present, and research is being actively conducted on this. In recent years, the method of injecting anti-vascular endothelial growth factor antibodies (Anti-VEGF antibody) such as aflibercept, ranibizumab, and bevacizumab into the eye has been mainly used, but there are disadvantages such as the need for repeated administration and high cost.

[0006] Therefore, the present inventors have studied substances that are effective in treating macular degeneration, and as a result, have identified a novel peptide that has not only excellent stability and solubility but also an excellent effect of inhibiting choroidal neovascularization, thereby completing the present invention.

[0007] Prior art literature

[0008] Patent Literature

[0009] Patent Document 1: Korean Patent Publication No. 10-2020-0060397 Summary of the invention

[0010] Technical issues

[0011] The object of the present invention is to provide a pharmaceutical composition for preventing or treating macular degeneration, which comprises a peptide as shown in Chemical Formula 1.

[0012] Furthermore, an object of the present invention is to provide a pharmaceutical composition for preventing or treating macular degeneration, which comprises a peptide consisting of the amino acid sequences shown in SEQ ID NO: 1 to SEQ ID NO: 45.

[0013] Technical Solution

[0014] The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, characterized in that it comprises a peptide as shown in the following Chemical Formula 1.

[0015] Chemical formula 1:

[0016] X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7

[0017] In the above formula, X 1An amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline,

[0018] X 2 is glycine,

[0019] X 3 Glutamine or D-Glutamine,

[0020] X 4 is an amino acid selected from the group consisting of aspartic acid (Aspartate), D-aspartic acid (D-Aspartate), glutamic acid (Glutamate) and D-glutamic acid (D-Glutamate),

[0021] X 5 It is a non-polar amino acid.

[0022] X 6 Not present, or Leucine or D-Leucine,

[0023] X 7 does not exist, or is an amino acid selected from the group consisting of Alanine, D-Alanine and Alanine-isopropyl ester,

[0024] Among them, when X 6 When X does not exist, 7 Doesn't exist either.

[0025] In one embodiment, in the above formula, X 1It may be an amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline,

[0026] X 2 It can be glycine,

[0027] X 3 It can be glutamine or D-glutamine.

[0028] X 4 It may be an amino acid selected from the group consisting of aspartic acid (Aspartate), D-aspartic acid (D-Aspartate), glutamic acid (Glutamate) and D-glutamic acid (D-Glutamate),

[0029] X 5 It can be glycine, phenyl-glycine, alanine, valine, leucine, tert-leucine and 2-aminoisobutyric acid.

[0030] X 6 It may not exist, or it may be leucine or D-leucine.

[0031] X 7 may be absent, or may be an amino acid selected from the group consisting of alanine, D-alanine, and alanine-isopropyl ester, wherein when X 6 When X does not exist, 7 Doesn't exist either.

[0032] In one embodiment, in the above formula, X 1 It may be an amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline,

[0033] X 2 It can be glycine,

[0034] X 3 It can be glutamine or D-glutamine.

[0035] X 4 It may be an amino acid selected from the group consisting of aspartic acid (Aspartate), D-aspartic acid (D-Aspartate), glutamic acid (Glutamate) and D-glutamic acid (D-Glutamate),

[0036] X 5 It can be a non-polar amino acid.

[0037] X 6 It can be leucine or D-leucine,

[0038] X 7 The amino acid may be selected from the group consisting of alanine, D-alanine, and alanine-isopropyl ester.

[0039] In one embodiment, in the above formula, X 1It may be an amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline,

[0040] X 2 It can be glycine,

[0041] X 3 It can be glutamine or D-glutamine.

[0042] X 4 It may be an amino acid selected from the group consisting of aspartic acid (Aspartate), D-aspartic acid (D-Aspartate), glutamic acid (Glutamate) and D-glutamic acid (D-Glutamate),

[0043] X 5 It may be an amino acid selected from the group consisting of glycine, phenyl-glycine, alanine, valine, leucine, tert-leucine and 2-aminoisobutyric acid,

[0044] X 6 It can be leucine or D-leucine,

[0045] X 7 The amino acid may be selected from the group consisting of alanine, D-alanine, and alanine-isopropyl ester.

[0046] In one embodiment, in the above formula, X 1It may be an amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline,

[0047] X 2 It can be glycine,

[0048] X 3 It can be glutamine or D-glutamine.

[0049] X 4 It can be glutamic acid (Glutamate) or D-glutamic acid (D-Glutamate),

[0050] X 5 It may be 2-aminoisobutyric acid,

[0051] X 6 It can be leucine or D-leucine,

[0052] X 7 The amino acid may be selected from the group consisting of alanine, D-alanine, and alanine-isopropyl ester.

[0053] The composition of the present invention may comprise any peptide selected from the group consisting of the amino acid sequences shown in SEQ ID NO: 1 to SEQ ID NO: 45, and preferably, may comprise a peptide consisting of the amino acid sequence shown in SEQ ID NO: 43.

[0054] The peptide of the present invention has an effect of inhibiting choroidal neovascularization (CNV).

[0055] The macular degeneration of the present invention may be one or more selected from the group consisting of wet macular degeneration, dry macular degeneration and age-related macular degeneration.

[0056] The present invention provides a method for treating macular degeneration, comprising the step of administering a peptide represented by the following Chemical Formula 1 to a subject suffering from macular degeneration.

[0057] Chemical formula 1:

[0058] X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7

[0059] In the above formula, X 1 An amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline,

[0060] X 2 is glycine,

[0061] X 3 Glutamine or D-Glutamine,

[0062] X 4 is an amino acid selected from the group consisting of aspartic acid (Aspartate), D-aspartic acid (D-Aspartate), glutamic acid (Glutamate) and D-glutamic acid (D-Glutamate),

[0063] X 5 It is a non-polar amino acid.

[0064] X 6 Not present, or Leucine or D-Leucine,

[0065] X 7 does not exist, or is an amino acid selected from the group consisting of Alanine, D-Alanine and Alanine-isopropyl ester,

[0066] Among them, when X 6 When X does not exist, 7 Doesn't exist either.

[0067] The present invention provides a composition for treating or preventing macular degeneration, comprising the peptide shown in the above Chemical Formula 1.

[0068] The present invention provides a use of a composition comprising a peptide as shown in the above Chemical Formula 1 for treating or preventing macular degeneration.

[0069] Effects of the Invention

[0070] The peptide of the present invention has excellent stability and solubility, and has an excellent effect of inhibiting choroidal neovascularization, which is a major cause of macular degeneration, and can be usefully used for preventing or treating macular degeneration. BRIEF DESCRIPTION OF THE DRAWINGS

[0071] Figure 1 as well as Figure 2 The results of Fundus Fluorescein Angiography (FFA) measurement of CNV by the peptide of the present invention and calculation of Corrected Total Fluorescence (CTF) are shown.

[0072] Figure 3 as well as Figure 4 The results of optical coherence tomography (OCT) measurement of CNV by the peptides of the present invention and calculation of CNV lesion size are shown.

[0073] Figure 5 The results of electroretinography of the peptides of the present invention on CNV are shown.

[0074] Figure 6 as well as Figure 7 The results of Fundus Fluorescein Angiography (FFA) measurement of CNV and quantification of vascular leakage using the peptide of Example 43 (002-175) of the present invention and an eye drop solution containing the peptide are shown.

[0075] Figure 8 as well as Fig. 9 The results of optical coherence tomography (OCT) measurement of CNV and calculation of CNV lesion size using the peptide of Example 43 (002-175) of the present invention and an eye drop solution containing the peptide are shown.

[0076] Fig.10 as well as Fig.11 The results of Fundus Fluorescein Angiography (FFA) measurement of CNV and calculation of the area of ​​new blood vessels using an eye drop solution containing the peptide of Example 43 (002-175) of the present invention are shown. DETAILED DESCRIPTION

[0077] Hereinafter, the embodiments and examples of the present invention will be described in detail with reference to the accompanying drawings so that those skilled in the art can easily implement the present invention. However, the present invention can be implemented in various forms and is not limited to the embodiments and examples described herein.

[0078] Throughout the specification of the present invention, when a part “includes” a certain structural element, unless otherwise specifically described to the contrary, it means that other structural elements may also be included rather than excluding other structural elements.

[0079] The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, characterized in that it comprises a peptide as shown in the following Chemical Formula 1.

[0080] Chemical formula 1:

[0081] X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7

[0082] In the above formula, X 1An amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline,

[0083] X 2 is glycine,

[0084] X 3 Glutamine or D-Glutamine,

[0085] X 4 is an amino acid selected from the group consisting of aspartic acid (Aspartate), D-aspartic acid (D-Aspartate), glutamic acid (Glutamate) and D-glutamic acid (D-Glutamate),

[0086] X 5 It is a non-polar amino acid.

[0087] X 6 Not present, or Leucine or D-Leucine,

[0088] X 7 does not exist, or is an amino acid selected from the group consisting of Alanine, D-Alanine and Alanine-isopropyl ester,

[0089] Among them, when X 6 When X does not exist, 7 Doesn't exist either.

[0090] The peptide of the present invention may be a peptide selected from the group consisting of the peptides shown in Table 1 below.

[0091] Table 1

[0092]

[0093]

[0094] The term "macular degeneration" used in the present invention refers to a disease in which the function of the macula is reduced and vision is reduced due to aging, genetic factors, toxicity, inflammation, etc., and in severe cases, the disease may lead to complete loss of vision.

[0095] In the present invention, the above-mentioned macular degeneration may be wet macular degeneration, dry macular degeneration, and age-related macular degeneration, and is not limited thereto.

[0096] The term "choroidal neovascularization (CNV)" used in the present invention refers to the process of generating new choroidal capillaries. The choroid is a highly vascularized membrane of the eyeball, and is a complex network of tiny capillaries that provide nutrition to the iris and retina located around it. Pathologically, choroidal neovascularization refers to damage to the subretinal space due to abnormal blood vessels forming the choroid from the choroid and structural deformation and destruction of Bruch's membrane.

[0097] The term "angiogenesis" used in the present invention refers to the process of forming new blood vessels, that is, new blood vessels are generated in cells, tissues or organs, and "neovascularization" refers to blood vessels newly formed by the angiogenesis process. In the present invention, "angiogenesis" and "neovascularization" can be recorded interchangeably.

[0098] The CNV animal model used in the present invention is a mouse model in which the choroid of C57BL / 6 mice is irradiated with laser by a laser slit system to induce lesions. The laser-induced CNV model first described in 1979 uses photocoagulation to destroy Bruch's membrane to induce the growth of choroidal neovascularization to the retinal area. From the point of view that the neovascularization begins to form from the choroid, it is similar to the occurrence form of neovascularization disease occurring in the human retina, namely wet macular degeneration (wet AMD). In addition, the above-mentioned laser-induced CNV model successfully predicts the clinical efficacy of anti-vascular endothelial growth factor (VEGF) treatment for neovascular AMD, and is an animal model used in the development stage of existing therapeutic agents (Gong Y, Li J, Sun Y, Fu Z, Liu CH, Evans L, et al. (2015) Optimization of an Image-Guided Laser-Induced Choroidal Neovascularization Model in Mice. PLoS ONE 10 (7)).

[0099] In the present invention, Pro is proline,

[0100] Hyp is trans-4-hydroxy-L-proline.

[0101] D Hyp is trans-4-hydroxy-D-proline.

[0102] cis-4F-Pro is cis-4-fluoro-L-proline.

[0103] 4,4-difluoro-Pro is 4,4-difluoro-L-proline.

[0104] 4-methylene-Pro is 4-methylene-L-proline,

[0105] 4,4-dimethyl Pro is 4,4-dimethyl-L-proline.

[0106] trans-4NH 2-Pro is trans-4-amino-L-proline,

[0107] Gly is glycine,

[0108] Gln is glutamine.

[0109] D-Gln is D-Glutamine.

[0110] Ala is alanine,

[0111] D-Ala is D-Alanine.

[0112] Val is valine.

[0113] Leu is leucine,

[0114] D-Leu is D-leucine.

[0115] Ile is isoleucine,

[0116] Met is methionine.

[0117] Tert-Leu is tert-leucine, L-α-tert-butylglycine,

[0118] Aib is 2-aminoisobutyric acid.

[0119] Isopropyl ester (IPE) is a derivative in which the terminal group of an amino acid is replaced by isopropyl ester.

[0120] Ser is serine,

[0121] Thr is threonine,

[0122] Cys stands for cysteine.

[0123] Asn is asparagine.

[0124] Phe is phenylalanine.

[0125] Tyr is tyrosine,

[0126] Trp is tryptophan.

[0127] Lys is lysine.

[0128] Arg is arginine.

[0129] His is histidine.

[0130] Asp is aspartate or aspartic acid.

[0131] D-Asp is D-Aspartate or D-Aspartic acid.

[0132] Glu is glutamate or glutamic acid.

[0133] D-Glu is D-glutamate (Glutamate) or D-glutamic acid (Glutamic acid).

[0134] In the present invention, polar amino acids refer to amino acids whose side chains have polarity in the chemical structure of the amino acids, including Thr, Ser, Cys, Asn, Gln, Asp, Glu, His, Lys, Arg, but are not limited thereto.

[0135] In the present invention, non-polar amino acids refer to amino acids whose side chains do not have polarity in the chemical structure of the amino acid, including Met, Leu, Pro, Ala, Gly, Val, Ile, Aib, but are not limited thereto.

[0136] The term "prevention" used in the present invention refers to all actions to inhibit or delay the onset of a disease by administering a composition, and "treatment" refers to all actions to improve or beneficially change the symptoms of individuals suspected of or suffering from a disease by administering a composition.

[0137] Hereinafter, the present invention will be described in more detail by way of examples, but the following examples are only for the purpose of illustration and are not intended to limit the scope of the present invention.

[0138] Preparation Example

[0139] The peptide of the present invention is synthesized based on the conventionally known solid phase peptide synthesis method (SPPS), and the preparation process includes the following steps.

[0140] Step 1: Resin soaking and sample loading

[0141] Step 2: Solid Phase Peptide Synthesis (SPPS)

[0142] Step 3: Deprotected peptide synthesis (global cleavage)

[0143] Step 4: First purification and concentration / Second purification and concentration

[0144] Step 5: Freeze Drying

[0145] The above-mentioned solid phase peptide synthesis method (SPPS) includes the steps of loading the first amino acid into the resin and deprotecting the amino acid with Fmoc at the N-terminus, then coupling the amino acid according to the amino acid sequence, and synthesizing the protected peptide in a solid phase reactor. In addition, the above-mentioned amino acid coupling includes the steps of removing the Fmoc at the N-terminus of the amino acid after loading the first amino acid into the resin; removing the solvent and washing the resin after the reaction is completed; coupling the next amino acid according to the sequence; removing the solvent and washing the resin after the reaction is completed; and then repeating the above process until the final amino acid sequence is generated.

[0146] The α-amine group of each amino acid is protected by the Fmoc group that is fragile to the base, and the functional group of the side chain is protected by a group that is fragile to the acid. All amino acids except Gly and Aib are L-configuration, among which the following amino acids Hyp (tBu), Glu (tBu), and Gln (Trt) have unique protecting groups. Moreover, amino acids such as Ala, Leu, Aib, and Gly do not have protecting groups on the side chains. Therefore, after completing the amino acid coupling according to the sequence, the resin and the protecting groups are removed from the peptide to obtain a crude peptide. Then, the peptide compounds of Examples 1 to 45 are obtained by purification, concentration, and freeze drying.

[0147] Test Example 1

[0148] Evaluation of the inhibitory effect of peptides on choroidal neovascularization: Measurement of the fluorescence value of the CNV region (CTF; Corrected total fluorescence)

[0149] An experiment was performed as follows to evaluate the choroidal neovascularization (CNV) inhibitory effect of the peptide of the present invention.

[0150] 7-8 week old C57BL / 6 mice were instilled with mydriatic to dilate the pupils and anesthetized by intraperitoneal injection of Ketamine (50 mg / Kg) and Rompun (23.32 mg / Kg). Laser was irradiated to the choroid of each eyeball of the mouse 4 times in the directions of 12 o'clock, 3 o'clock, 6 o'clock, and 9 o'clock using a slit-lamp laser injection system. In this case, the laser irradiation conditions were 532 nm, 80 msec, and 240 mW. Immediately after laser irradiation, 1 ul of a peptide at a concentration of 10 mg / mL or aflibercept at a concentration of 20 mg / mL dissolved in PBS was injected into the vitreous body using a syringe. Ten days after administration, the mice were anesthetized and 2% fluorescein was intraperitoneally administered to stain the blood vessels. The retina was photographed 2 to 3 minutes after the administration of fluorescein. The size and fluorescence value of CNV lesions induced by laser were measured using the imageJ program, and the background was removed to reduce the difference between individuals to calculate the corrected total fluorescence (CTF) and compare the values ​​of each group. The results of all experiments were expressed as mean ± standard deviation, and the significance was verified by one-way ANOVA and Kruskal-Wallis test.

[0151] The above experimental results are shown in Table 2 below. Figure 1 as well as Figure 2 middle.

[0152] Table 2

[0153]

[0154]

[0155] As shown in Table 2, Figure 1 as well as Figure 2As shown, the results of measuring the fluorescence values ​​of the CNV region confirmed that the peptides of the present invention have a CNV inhibitory effect, especially the peptides of Example 1 (002-053), Example 7 (002-076), Example 8 (002-077), Example 9 (002-078), Example 13 (002-090), Example 14 (002-055), Example 15 (002-080), Example 17 (002-084), Example 23 (002-087), Example 27 (002-091) and Example 43 (002-175) showed very excellent inhibitory effects.

[0156] Therefore, it was found that the peptide of the present invention has excellent CNV inhibitory effect.

[0157] Test Example 2

[0158] Evaluation of the inhibitory efficacy of peptides on choroidal neovascularization: Optical Coherence Tomography

[0159] An experiment was performed as follows to evaluate the choroidal neovascularization (CNV) inhibitory efficacy of the peptides of the present invention.

[0160] 7-8 week old C57BL / 6 mice were instilled with mydriatics to dilate the pupils and anesthetized by intraperitoneal injection of Ketamine (50 mg / Kg) and Rompun (23.32 mg / Kg). The laser was irradiated to the choroid of each eyeball of the mouse 4 times in the directions of 12 o'clock, 3 o'clock, 6 o'clock, and 9 o'clock using a slit-lamp laser injection system. In this case, the laser irradiation conditions were 532 nm, 80 msec, and 240 mW. After laser irradiation, 1 ul of a peptide at a concentration of 10 mg / mL or aflibercept at a concentration of 20 mg / mL dissolved in PBS was immediately injected into the vitreous using a syringe. The mice were anesthetized 10 days after administration, and then each burn was penetrated with an OCT beam and calculated using the ImageJ program to express the changes in μm. 2 = represents the CNV lesion induced by laser. The results of all experiments are expressed as mean ± SD, and the significance was verified by one-way ANOVA and Kruskal-Wallis test.

[0161] The above experimental results are shown in Table 3 below. Figure 3 as well as Figure 4 middle.

[0162] Table 3

[0163]

[0164] As shown in Table 3, Figure 3 as well as Figure 4 As shown in Figure 1, the size of CNV lesions was measured, and it was confirmed that the size of CNV lesions was reduced when the peptide of the present invention was injected. Therefore, it was found that the peptide of the present invention has an excellent CNV inhibitory effect.

[0165] Test Example 3

[0166] Evaluation of the inhibitory effect of peptides on choroidal neovascularization: Electroretinography

[0167] An experiment was performed as follows to evaluate the choroidal neovascularization (CNV) inhibitory efficacy of the peptides of the present invention.

[0168] 7-8 week old C57BL / 6 mice were instilled with mydriatic to dilate the pupil, and anesthetized by intraperitoneal injection of Ketamine (50 mg / Kg) and Rompun (23.32 mg / Kg). The laser was irradiated to the choroid of each eyeball of the mouse 4 times in the directions of 12 o'clock, 3 o'clock, 6 o'clock, and 9 o'clock using a slit-lamp laser injection system. In this case, the laser irradiation conditions were 532 nm, 80 msec, and 240 mW. Immediately after laser irradiation, 1 ul of a peptide at a concentration of 10 mg / mL or aflibercept at a concentration of 20 mg / mL dissolved in PBS was injected into the vitreous using a syringe. Dark adaptation was performed for more than 12 hours for electroretinogram analysis. After the mice were anesthetized and dilated in a dark room, the ground electrode was touched to the tail, the reference electrode to the head, and the corneal electrode to the cornea to perform electroretinography. Flash intensity of 0.9 cd·sec / m 2The single white light stimulation of the retina was used to obtain the response value, and the amplitude from the trough of the a-wave to the apex of the b-wave was measured and evaluated as an indicator of retinal function. The results of all tests were expressed as mean ± standard deviation, and the significance was verified by one-way ANOVA and Kruskal-Wallis test.

[0169] The above experimental results are shown in Table 4 and Figure 5 middle.

[0170] Table 4

[0171]

[0172]

[0173] As shown in Table 3 and Figure 5 As shown in FIG. 1 , the amplitude of the b wave was measured and it was confirmed that the amplitude of the b wave was increased when the peptide of the present invention was injected. Therefore, it was found that the peptide of the present invention has an excellent CNV inhibitory effect.

[0174] Test Example 4

[0175] Peptide stability evaluation

[0176] An experiment was performed as follows to evaluate the stability of the peptides of the present invention.

[0177] The stability was confirmed by analyzing the content of the peptide in an aqueous solution under severe conditions of a temperature of 40° C. and a humidity of 75%, and then analyzed by HPLC under the following conditions.

[0178] Analytical column: C18 (4.6Y250mm, 5μm, YMC Hydrosphere)

[0179] Analysis wavelength: UV spectrophotometer (210nm)

[0180] Injection volume / flow rate: 10μL / 0.8mL / min

[0181] Column temperature: 45°C

[0182] Mobile phase: 0.1M phosphate buffer methanol mixture (83:17)

[0183] The above experimental results are shown in Table 5 below.

[0184] Table 5

[0185] Example Peptide number Initial content (%) Content after 7 days (%) Reduction rate (%) 40 002-132 96.123 95.685 0.438 41 002-165 98.155 97.555 0.600 43 002-175 96.917 96.562 0.355 44 002-176 98.390 97.785 0.605 45 002-177 98.586 98.147 0.439

[0186] As shown in Table 5 above, the results of evaluating the stability confirmed that the content of the peptide of the present invention was maintained at about 95% or more after 7 days, and the reduction rate after 7 days was less than about 1%, indicating that the stability was very excellent. In particular, Example 43 (002-175) showed the best stability. Therefore, it can be seen that the peptide of the present invention has excellent stability.

[0187] Test Example 5

[0188] Evaluation of peptide solubility

[0189] An experiment was performed as follows to evaluate the solubility of the peptides of the present invention.

[0190] The solubility test was conducted based on the Korean Pharmacopoeia method, and the solubility was judged by the degree of dissolution within 30 minutes when 0.1 g of the peptide was put into 10 mL of water and mixed with vigorous shaking for 30 seconds every 5 minutes at a temperature of 20±5°C.

[0191] The above experimental results are shown in Table 6 below.

[0192] Table 6

[0193] Example Peptide number Solubility (mg / ml) 40 002-132 330.0 43 002-175 500.0 44 002-176 100.0

[0194] As shown in Table 6, the results of the solubility measurement showed that the peptides of the present invention exhibited excellent solubility, and in particular, Example 43 (002-175) exhibited the most excellent solubility. Therefore, it was found that the peptides of the present invention have excellent solubility.

[0195] Test Example 6

[0196] Evaluation of the inhibitory efficacy of peptide-containing eye drops on choroidal neovascularization

[0197] An experiment was conducted as follows to evaluate the choroidal neovascularization (CNV) inhibitory efficacy of the eye drops containing the peptide of Example 43 (002-175) confirmed to be excellent by the above-mentioned Test Examples.

[0198] 7-8 week old C57BL / 6 mice were instilled with mydriatic to dilate the pupil, and anesthetized by intraperitoneal injection of Ketamine (50 mg / Kg) and Rompun (23.32 mg / Kg). The laser was irradiated to the choroid of each eyeball of the mouse 4 times in the directions of 12 o'clock, 3 o'clock, 6 o'clock, and 9 o'clock using a slit-lamp laser injection system. In this case, the laser irradiation conditions were 532 nm, 80 msec, and 240 mW. Three days after laser irradiation, 1 μL of aflibercept dissolved in PBS at a concentration of 20 mg / mL was injected into the vitreous body using a syringe before administration, and the drugs prepared according to different concentrations were instilled into both eyes twice a day (5 μL / eye, AM: 9:00, FM: 04:00) for 11 days. Six, ten, and fourteen days after laser induction, mice were anesthetized and 2% fluorescein was intraperitoneally administered to stain blood vessels. The retina was photographed 2 to 3 minutes after the administration of fluorescein. The size and fluorescence value of the CNV lesions induced by the laser were measured using the imageJ program, and the background was removed to reduce the difference between individuals to calculate the corrected total fluorescence (CTF) and compare the values ​​of each group. In addition, mice were anesthetized six, ten, and fourteen days after laser induction, and then the OCT beam was penetrated through each burn and the ImageJ program was used to calculate the values ​​in μm. 2 The results of all experiments were expressed as mean ± standard deviation and the significance was verified by one-way ANOVA and Kruskal-Wallis test. Figures 6 to 9 middle.

[0199] like Figure 6 as well as Figure 7 As shown, the results of measuring the fluorescence value of the CNV region showed that the eye drops containing the peptide of Example 43 (002-175) of the present invention showed excellent CNV inhibitory effect, especially, 14 days after administration, it showed a better inhibitory effect than aflibercept as a positive control group.

[0200] And, if Figure 8 as well as Fig. 9As shown, the results of measuring the size of CNV lesions confirmed that the size of CNV lesions was reduced when the eye drops containing the peptide of Example 43 (002-175) of the present invention were administered, and in particular, the size was reduced to a similar level as compared with aflibercept as a positive control group.

[0201] Therefore, it was found that the eye drops containing the peptide of Example 43 (002-175) of the present invention have excellent CNV inhibitory effect.

[0202] Test Example 7

[0203] Evaluation of the neovascularization inhibitory efficacy of peptide-containing eye drops

[0204] The symptom of neovascular macular degeneration is retinal angiomatous proliferation (RAP), which occurs in approximately 12 to 15% of newly diagnosed patients with neovascular macular degeneration. On the other hand, Vldlr is known to be one of the functional candidate genes for human macular degeneration, and the Vldlr knockout (- / -) mice show subretinal angiogenesis and retinal angiomatous proliferation. Therefore, the following experiment was conducted to evaluate the neovascularization inhibitory efficacy of the eye drops containing Example 43 (002-175), which was confirmed to be excellent by the above test example, using Vldlr knockout (- / -) mice as an animal model of neovascular macular degeneration.

[0205] Give Vldlr from 6 weeks of age (P42) to 14 weeks of age (P98) - / - The mice were instilled with eye drops containing the peptide of Example 43 (002-175) twice a day, and 1 μL of aflibercept at a concentration of 20 mg / mL was intraocularly injected once into the vitreous of 6-week-old mice as a positive control group. Mydriatics were instilled into the eyeballs of the mice to dilate the pupils, and then anesthetized by intraperitoneal injection of ketamine (50 mg / Kg) and Rompun (23.32 mg / Kg), and 2% fluorescein was injected intraperitoneally to stain the blood vessels. Images were obtained by retinal fluorescence imaging, and the lesion area was calculated using the imageJ program. The experimental results are shown in Fig.10 as well as Fig.11 middle.

[0206] like Fig.10 as well as Fig.11As shown in the results of calculation of the neovascularization area, the lesion size of the group administered with aflibercept (AF) as the positive control group decreased rapidly after 1 week of administration (P49), but slowly increased again from the 2nd week, and showed a size similar to that of the vehicle-administered group as the negative control group after 8 weeks (P98). In contrast, the lesion size of the group administered with the eye drops containing the peptide of Example 43 (002-175) of the present invention slowly decreased, and after 8 weeks of administration, the lesion size was suppressed (P98).

[0207] Therefore, it was found that the eye drops containing the peptide of Example 43 (002-175) of the present invention have excellent angiogenesis inhibitory effect.

Claims

1. A pharmaceutical composition for preventing or treating macular degeneration, characterized in that: The invention comprises a peptide as shown in the following chemical formula 1: Chemical formula 1: X1-X2-X3-X4-X5-X6-X7 In the above formula, X1 is an amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline, X2 is glycine, X3 is glutamine or D-glutamine, X4 is an amino acid selected from the group consisting of aspartic acid, D-aspartic acid, glutamic acid and D-glutamic acid, X5 is a non-polar amino acid. X6 is absent, or is leucine or D-leucine, X7 is absent or is an amino acid selected from the group consisting of alanine, D-alanine and alanine isopropyl ester, Among them, when X6 does not exist, X7 does not exist either.

2. The pharmaceutical composition for preventing or treating macular degeneration according to claim 1, characterized in that: In the above formula, X1 is an amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline, X2 is glycine, X3 is glutamine or D-glutamine, X4 is an amino acid selected from the group consisting of aspartic acid, D-aspartic acid, glutamic acid and D-glutamic acid, X5 is an amino acid selected from the group consisting of glycine, phenylglycine, alanine, valine, leucine, tert-leucine and 2-aminoisobutyric acid, X6 is absent, or is leucine or D-leucine, X7 is absent or is an amino acid selected from the group consisting of alanine, D-alanine and alanine isopropyl ester.

3. The pharmaceutical composition for preventing or treating macular degeneration according to claim 1, characterized in that: In the above formula, X1 is an amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline, X2 is glycine, X3 is glutamine or D-glutamine, X4 is an amino acid selected from the group consisting of aspartic acid, D-aspartic acid, glutamic acid and D-glutamic acid, X5 is a non-polar amino acid. X6 is leucine or D-leucine, X7 is an amino acid selected from the group consisting of alanine, D-alanine and alanine isopropyl ester.

4. The pharmaceutical composition for preventing or treating macular degeneration according to claim 1, characterized in that: In the above formula, X1 is an amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline, X2 is glycine, X3 is glutamine or D-glutamine, X4 is an amino acid selected from the group consisting of aspartic acid, D-aspartic acid, glutamic acid and D-glutamic acid, X5 is an amino acid selected from the group consisting of glycine, phenylglycine, alanine, valine, leucine, tert-leucine and 2-aminoisobutyric acid, X6 is leucine or D-leucine, X7 is an amino acid selected from the group consisting of alanine, D-alanine and alanine isopropyl ester.

5. The pharmaceutical composition for preventing or treating macular degeneration according to claim 1, characterized in that: In the above formula, X1 is an amino acid selected from the group consisting of proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, cis-4-fluoro-L-proline, 4,4-difluoro-L-proline, 4-methylene-L-proline, 4,4-dimethyl-L-proline and trans-4-amino-L-proline, X2 is glycine, X3 is glutamine or D-glutamine, X4 is glutamic acid or D-glutamic acid, X5 is 2-aminoisobutyric acid, X6 is leucine or D-leucine, X7 is an amino acid selected from the group consisting of alanine, D-alanine and alanine isopropyl ester.

6. The pharmaceutical composition for preventing or treating macular degeneration according to claim 1, characterized in that: It comprises any peptide selected from the group consisting of the amino acid sequences shown in SEQ ID NO: 1 to SEQ ID NO:

45.

7. The pharmaceutical composition for preventing or treating macular degeneration according to claim 1, characterized in that: It comprises a peptide consisting of the amino acid sequence shown in SEQ ID NO:

43.

8. The pharmaceutical composition for preventing or treating macular degeneration according to any one of claims 1 to 7, characterized in that: The above peptides inhibit choroidal neovascularization.

9. The pharmaceutical composition for preventing or treating macular degeneration according to claim 1, characterized in that: The macular degeneration is at least one selected from the group consisting of wet macular degeneration, dry macular degeneration and age-related macular degeneration.